2 Million Treatments Worldwide with DUROLANE

It may be hard to believe, but Bioventus is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE, the original single injection hyaluronic acid therapy. Since 2001, DUROLANE has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of osteoarthritis pain.

Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One®. It has longer lasting pain relief versus a steroid injection, is safe and its repeated use does not increase the incidence of adverse events for patients.

“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally. Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”

We asked the marketing leaders who steward the DUROLANE brand around the world for their thoughts on this milestone.

Carl Liebert

“For me, this milestone is just one more thing that gives me pride in the DUROLANE brand.  It’s long history of helping people though established efficacy, it’s unique formulation and much more make it a great product to market and gives me confidence that we will continue to succeed with it globally.” – Carl Liebert, Global Brand Strategy, Director of EXOGEN and HA.

Onno Siegersma

“DUROLANE is unique to its kind: DUROLANE has no competition! DUROLANE didn’t change in 20 years, there is no version 2.0: the word ‘original’ has value of its own! In 20 years, DUROLANE didn’t need a line extension to serve customer and patient’s needs, DUROLANE was 20 years ago its time ahead! DUROLANE manages the need for 3- and 5-injection and location for pain. DUROLANE treats multiple joints: DUROLANE is All for One and One for All! DUROLANE belongs to the most clinical documented HA Brands. DUROLANE is as good as it can get! DUROLANE was introduced almost 20 years ago, used by over 15,000 healthcare professionals worldwide and exceeds 2 million OA patient treatments: DUROLANE Numbers Speak!” – Onno Siegersma, Director of International Marketing.

Cathy Lo Re

“Allow me to begin with the end – I love DUROLANE! DUROLANE is one of the reasons I get up in the morning – to help others with OA. DUROLANE has helped my mother, cousin and friends. I’ve read many studies, spoken with many physicians and patients however it’s seeing my mother walk better because of DUROLANE that makes it personal. We’re not supposed to have a favourite; DUROLANE is my favourite. Over the years, I have been accused, several times, of being too passionate about DUROLANE – I am guilty as charged. I love DUROLANE!” – Cathy Lo Re, Director of Marketing, Canada.

 

Derek Hurdle

“When I hear the 2 million number there is an immediate sense of pride-that is 2 million patients that we have impacted globally over all these years.  We have taken DUROLANE to a position of market leadership in Canada and in the US Market DUROLANE was the most successful launch in market history.  I am looking forward to the day when we (and we will) claim worldwide market leadership.  DUROLANE truly is in a class by itself.”  – Derek Hurdle, Director Marketing, North America.

Ray Perry

“DUROLANE truly provides a difference in a class that is hard to distinguish among product. I know if anyone of my family needed a HA injection I would insist on DUROLANE and fight for it.”  – Ray Perry, Senior Product Manager, US HA Portfolio.